Connect Biopharma Holdings Limited (CNTB)

1,3500 -0,1500 (-10,00%) Alla chiusura: 04:00PM EDT

Connect Biopharma Holdings Limited

12265 El Camino Real
Suite 350
San Diego, CA 92130
United States
858 727 1040
https://www.connectbiopharm.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 81

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Wubin Pan M.B.A., Ph.D.	Co-Founder, President & Chairman of the Board of Directors	N/D	N/D	1965
Dr. Zheng Wei Ph.D.	Co-Founder, CEO & Director	N/D	N/D	1964
Mr. Steven Chan	Chief Financial Officer	N/D	N/D	1972
Mr. Jiang Bian J.D.	General Counsel & Chief Compliance Officer	N/D	N/D	N/D
Dr. Lei Sun Ph.D.	VP of Biologics & Head of CMC	N/D	N/D	1964
Dr. Raul Collazo Ph.D.	VP & Global Head of Medical Affairs	N/D	N/D	N/D
Dr. Malinda V. Longphre Ph.D.	VP & Head of US Clinical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Governance aziendale

L'ISS Governance QualityScore di Connect Biopharma Holdings Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.